NCT01106027View on ClinicalTrials.gov

Dosing Regimen of Eculizumab Added to Conventional Treatment in Positive Crossmatch Deceased Donor Kidney Transplant

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

March 31, 2010

Primary Completion Date

August 19, 2016

Study Completion Date

August 19, 2016

Conditions
Kidney Transplant
Interventions
DRUG

Eculizumab

Eculizumab 900 mg and 1200 mg, administered intravenously (IV)

Trial Locations (1)

55901

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

Alexion Pharmaceuticals, Inc.

INDUSTRY

lead

Mayo Clinic

OTHER